Actinium Pharmaceuticals, Inc.(ATNM)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ATNM Actinium Pharmaceuticals, Inc.

盘前交易 09-29 07:00:05 EDT

1.18

-0.02

-1.67%

最高1.20	最低1.17	成交量7.54万
今开1.18	昨收1.20	日振幅2.50%
总市值3,702万	流通市值3,645万	总股本3,137万
成交额8.92万	换手率0.24%	流通股本3,089万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ATNM","market":"US","secType":"STK","nameCN":"Actinium Pharmaceuticals, Inc.","latestPrice":1.18,"timestamp":1790625600000,"preClose":1.2,"halted":0,"volume":75358,"delay":0,"changeRate":-0.016666666666666684,"floatShares":30887900,"shares":31374994,"eps":0.355888,"marketStatus":"盘前交易","change":-0.02,"latestTime":"09-29 07:00:05 EDT","open":1.18,"high":1.2,"low":1.17,"amount":89246.554758,"amplitude":0.025,"askPrice":1.3,"askSize":5,"bidPrice":1.08,"bidSize":200,"shortable":3,"etf":0,"ttmEps":0.355888,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790688600000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"AMEX","adjPreClose":1.18,"postHourTrading":{"tag":"盘后","latestPrice":1.18,"preClose":1.18,"latestTime":"19:58 EDT","volume":2241,"amount":2644.4144,"timestamp":1790639938187,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.945345952020757,"impliedVol":0.0009,"impliedVolPercentile":0.856},"requestUrl":"/m/hq/s/ATNM","defaultTab":"news","newsList":[{"id":"1148190327","title":"Actinium Pharmaceuticals修订IND申请，新增CRADA及公司研究制造商；关键里程碑预计于2026年下半年至2027年达成","url":"https://stock-news.laohu8.com/highlight/detail?id=1148190327","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148190327?lang=zh_cn&edition=full","pubTime":"2026-08-15 05:04","pubTimestamp":1786741444,"startTime":"0","endTime":"0","summary":"Actinium Pharmaceuticals（股票代码：ATNM）——这家专注于放射性药物研发的生物制药公司，近日对其试验性新药（IND）申请进行了修订，旨在为合作研究与开发协议（CRADA）以及公司内部研究项目增添新的制造商。这一举措，标志着公司在推进其核心管线产品的过程中，进一步强化了供应链的稳定性和生产能力。随着修订的完成，一系列备受期待的里程碑事件也有望在2026年下半年至2027年期间实现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATNM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134694140","title":"Actinium任命资深肿瘤学专家Steffen Heeger博士为首席医疗官，以推动研发管线复兴","url":"https://stock-news.laohu8.com/highlight/detail?id=1134694140","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134694140?lang=zh_cn&edition=full","pubTime":"2026-06-01 20:00","pubTimestamp":1780315252,"startTime":"0","endTime":"0","summary":"Actinium Pharmaceuticals, Inc.（简称Actinium）宣布，任命在肿瘤学领域成就斐然的专家Steffen Heeger博士为首席医疗官。此项人事任命旨在驱动公司研发管线的重新焕发活力与加速发展。\nSteffen Heeger博士的加入，将为Actinium带来深厚的临床开发与战略规划经验。他将在领导公司现有及未来候选药物的临床开发项目中扮演关键角色，助力管线潜力的最大化释放。\n此举标志着Actinium致力于强化其领导团队，以推进创新疗法开发的坚定承诺。公司期待在Heeger博士的带领下，其研发管线能迎来新的发展篇章。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATNM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131243865","title":"Actinium制药公司公布ATNM-400泛癌种积极数据，在前列腺癌、肺癌及乳腺癌模型中展现广泛疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1131243865","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131243865?lang=zh_cn&edition=full","pubTime":"2026-04-22 19:03","pubTimestamp":1776855836,"startTime":"0","endTime":"0","summary":"Actinium Pharmaceuticals, Inc. 在2026年美国癌症研究协会年会上公布了其候选药物ATNM-400的引人注目的泛癌种研究数据。该数据表明，ATNM-400在前列腺癌、肺癌以及乳腺癌临床前模型中均显示出广泛的抗肿瘤疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATNM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107243994","title":"Actinium制药公司ATNM-400在前列腺癌模型中展现疗效，不受PSMA表达水平限制","url":"https://stock-news.laohu8.com/highlight/detail?id=1107243994","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107243994?lang=zh_cn&edition=full","pubTime":"2026-04-22 19:01","pubTimestamp":1776855700,"startTime":"0","endTime":"0","summary":"Actinium Pharmaceuticals, Inc. 宣布，其研发的靶向放射性药物ATNM-400，在临床前研究中取得了积极进展。研究数据显示，该药物不仅在PSMA高表达的前列腺癌模型中显示出强大的抗肿瘤活性，在PSMA低表达模型中同样表现出显著疗效。这一发现具有重要意义，因为它意味着ATNM-400的潜在治疗范围可能覆盖更广泛的前列腺癌患者群体，而不受其PSMA表达水平的严格限制，有望为那些目前治疗选择有限的患者提供新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATNM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156281519","title":"Actinium制药公司ATNM-400耐受性良好，有效剂量下未观察到体内毒性","url":"https://stock-news.laohu8.com/highlight/detail?id=1156281519","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156281519?lang=zh_cn&edition=full","pubTime":"2026-04-22 19:01","pubTimestamp":1776855694,"startTime":"0","endTime":"0","summary":"Actinium Pharmaceuticals公司宣布，其候选药物ATNM-400在有效剂量水平下展现出良好的耐受性特征。最新研究数据显示，该药物在实验过程中未引发任何体内毒性反应。这一积极结果为进一步临床开发奠定了坚实基础，表明ATNM-400在治疗窗内具有理想的安全性特征。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATNM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517798531","title":"Actinium Pharmaceuticals, Inc. (Delaware)盘中异动 股价大涨5.66%报1.12美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517798531","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517798531?lang=zh_cn&edition=full","pubTime":"2025-03-05 04:22","pubTimestamp":1741119741,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日04时22分，Actinium Pharmaceuticals, Inc. 股票出现波动，股价急速上涨5.66%。其相关个股中，Rapport Therapeutics, Inc.、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Estrella Immunopharma Inc C/Wts 29/09/2028涨幅较大，Aeon Biopharma, Inc.、Protagenic Therapeutics, Inc.、Windtree Therapeutics, Inc.较为活跃，换手率分别为1327.56%、1257.23%、1219.56%，振幅较大的相关个股有Cyclacel Pharmaceuticals Inc 6% Cnv Pfd Usd、Protagenic Therapeutics Inc C/Wts 29/04/2026 、Plus Therapeutics, Inc.，振幅分别为122.48%、68.89%、68.09%。Actinium Pharmaceuticals, Inc. 公司简介：Actinium Pharmaceuticals Inc是一家生物制药公司，致力于为缺乏有效治疗选择的癌症患者开发创新性靶向疗法。，目前在急性髓样白血病的临床试验中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305042221a25f667b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305042221a25f667b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ATNM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516658087","title":"Actinium Pharmaceuticals, Inc. (Delaware)盘中异动 股价大跌5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516658087","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516658087?lang=zh_cn&edition=full","pubTime":"2025-03-04 00:00","pubTimestamp":1741017619,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日00时00分，Actinium Pharmaceuticals, Inc. 股票出现异动，股价大幅下跌5.22%。其相关个股中，Bioxcel Therapeutics, Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Radiopharm Theranostics Limited涨幅较大，Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为3044.10%、143.00%、135.71%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Pliant Therapeutics, Inc.，振幅分别为206.20%、70.53%、50.09%。Actinium Pharmaceuticals, Inc. 公司简介：Actinium Pharmaceuticals Inc是一家生物制药公司，致力于为缺乏有效治疗选择的癌症患者开发创新性靶向疗法。，目前在急性髓样白血病的临床试验中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304000019a25d5bfe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304000019a25d5bfe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ATNM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516372987","title":"Actinium Pharmaceuticals, Inc. (Delaware)盘中异动 股价大涨5.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516372987","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516372987?lang=zh_cn&edition=full","pubTime":"2025-03-01 01:12","pubTimestamp":1740762727,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日01时12分，Actinium Pharmaceuticals, Inc. 股票出现异动，股价急速拉升5.45%。Actinium Pharmaceuticals, Inc. 股票所在的生物技术行业中，整体涨幅为0.52%。其相关个股中，Bioxcel Therapeutics, Inc.、Camp4 Therapeutics Corporation、Enveric Biosciences, Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Enveric Biosciences, Inc.、Virpax Pharmaceuticals, Inc.较为活跃，换手率分别为3078.25%、502.62%、371.70%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Cardio Diagnostics Holdings Inc C/Wts  To Pur Com、Nrx Pharmaceuticals Inc C/Wts 24/05/2026 ，振幅分别为57.80%、49.50%、48.19%。Actinium Pharmaceuticals, Inc. 公司简介：Actinium Pharmaceuticals Inc是一家生物制药公司，致力于为缺乏有效治疗选择的癌症患者开发创新性靶向疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301011207abe11033&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301011207abe11033&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ATNM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512431314","title":"Actinium Pharmaceuticals, Inc. (Delaware)盘中异动 临近收盘股价大跌5.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512431314","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512431314?lang=zh_cn&edition=full","pubTime":"2025-02-20 04:31","pubTimestamp":1739997081,"startTime":"0","endTime":"0","summary":"北京时间2025年02月20日04时31分，Actinium Pharmaceuticals, Inc. 股票出现波动，股价快速下挫5.56%。其相关个股中，Editas Medicine, Inc.、Osr Holdings, Inc.、Osr Holdings Inc C/Wts 02/09/2028 涨幅较大，Aditxt, Inc.、Alzamend Neuro, Inc.、Osr Holdings, Inc.较为活跃，换手率分别为705.12%、257.47%、235.20%，振幅较大的相关个股有Osr Holdings Inc C/Wts 02/09/2028 、Surrozen Inc C/Wts 01/08/2031 、Osr Holdings, Inc.，振幅分别为282.57%、280.70%、160.77%。Actinium Pharmaceuticals, Inc. 公司简介：Actinium Pharmaceuticals Inc是一家生物制药公司，致力于为缺乏有效治疗选择的癌症患者开发创新性靶向疗法。，目前在急性髓样白血病的临床试验中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220043121962905fa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220043121962905fa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ATNM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512416503","title":"Actinium Pharmaceuticals, Inc. (Delaware)盘中异动 早盘股价大涨5.65%报1.22美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512416503","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512416503?lang=zh_cn&edition=full","pubTime":"2025-02-18 22:38","pubTimestamp":1739889487,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日22时38分，Actinium Pharmaceuticals, Inc. 股票出现波动，股价快速上涨5.65%。Actinium Pharmaceuticals, Inc. 股票所在的生物技术行业中，整体涨幅为0.27%。Actinium Pharmaceuticals, Inc. 公司简介：Actinium Pharmaceuticals Inc是一家生物制药公司，致力于为缺乏有效治疗选择的癌症患者开发创新性靶向疗法。，目前在急性髓样白血病的临床试验中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218223807abd3b0b5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218223807abd3b0b5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ATNM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511614972","title":"Actinium Pharmaceuticals, Inc. (Delaware)盘中异动 下午盘股价大涨5.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511614972","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511614972?lang=zh_cn&edition=full","pubTime":"2025-02-15 04:19","pubTimestamp":1739564392,"startTime":"0","endTime":"0","summary":"北京时间2025年02月15日04时19分，Actinium Pharmaceuticals, Inc. 股票出现异动，股价急速拉升5.45%。其相关个股中，Moleculin Biotech, Inc.、Nls Pharmaceutics Ltd C/Wts 02/02/2026、Allogene Therapeutics, Inc.涨幅较大，Moleculin Biotech, Inc.、Cns Pharmaceuticals, Inc.、Virpax Pharmaceuticals, Inc.较为活跃，换手率分别为3171.83%、809.03%、631.75%，振幅较大的相关个股有Lexaria Bioscience Corp C/Wts 14/01/2026 、Moleculin Biotech, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 ，振幅分别为74.35%、71.65%、66.45%。Actinium Pharmaceuticals, Inc. 公司简介：Actinium Pharmaceuticals Inc是一家生物制药公司，致力于为缺乏有效治疗选择的癌症患者开发创新性靶向疗法。，目前在急性髓样白血病的临床试验中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502150419529885d609&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502150419529885d609&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ATNM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509789082","title":"Actinium Pharmaceuticals, Inc. (Delaware)盘中异动 快速跳水5.28%报1.17美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509789082","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509789082?lang=zh_cn&edition=full","pubTime":"2025-02-07 04:57","pubTimestamp":1738875460,"startTime":"0","endTime":"0","summary":"北京时间2025年02月07日04时57分，Actinium Pharmaceuticals, Inc. 股票出现异动，股价快速下挫5.28%。Actinium Pharmaceuticals, Inc. 股票所在的生物技术行业中，整体跌幅为0.51%。其相关个股中，Lipella Pharmaceuticals Inc.、Geovax Labs Inc C/Wts 29/09/2025、Nrx Pharmaceuticals Inc C/Wts 24/05/2026 涨幅较大，Lipella Pharmaceuticals Inc.、Transcode Therapeutics, Inc.、Ocean Biomedical, Inc.较为活跃，换手率分别为7130.44%、1780.86%、204.41%，振幅较大的相关个股有Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 ，振幅分别为125.58%、77.86%、65.64%。Actinium Pharmaceuticals, Inc. 公司简介：Actinium Pharmaceuticals Inc是一家生物制药公司，致力于为缺乏有效治疗选择的癌症患者开发创新性靶向疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207045740abc51f6e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207045740abc51f6e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ATNM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509625342","title":"Actinium Pharmaceuticals, Inc. (Delaware)盘中异动 下午盘急速上涨5.12%报1.23美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509625342","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509625342?lang=zh_cn&edition=full","pubTime":"2025-02-06 04:01","pubTimestamp":1738785690,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日04时01分，Actinium Pharmaceuticals, Inc. 股票出现异动，股价大幅上涨5.12%。Actinium Pharmaceuticals, Inc. 股票所在的生物技术行业中，整体涨幅为2.46%。Actinium Pharmaceuticals, Inc. 公司简介：Actinium Pharmaceuticals Inc是一家生物制药公司，致力于为缺乏有效治疗选择的癌症患者开发创新性靶向疗法。，目前在急性髓样白血病的临床试验中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025020604013096193c4e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025020604013096193c4e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ATNM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508144663","title":"Actinium Pharmaceuticals, Inc. (Delaware)盘中异动 股价大跌5.16%报1.10美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508144663","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508144663?lang=zh_cn&edition=full","pubTime":"2025-02-03 22:51","pubTimestamp":1738594285,"startTime":"0","endTime":"0","summary":"北京时间2025年02月03日22时51分，Actinium Pharmaceuticals, Inc. 股票出现异动，股价大幅跳水5.16%。Actinium Pharmaceuticals, Inc. 股票所在的生物技术行业中，整体跌幅为0.42%。Actinium Pharmaceuticals, Inc. 公司简介：Actinium Pharmaceuticals Inc是一家生物制药公司，致力于为缺乏有效治疗选择的癌症患者开发创新性靶向疗法。，目前在急性髓样白血病的临床试验中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203225125abc10bfa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203225125abc10bfa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ATNM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505209953","title":"Actinium Pharmaceuticals, Inc. (Delaware)盘中异动 大幅下跌5.00%报1.33美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2505209953","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2505209953?lang=zh_cn&edition=full","pubTime":"2025-01-22 00:28","pubTimestamp":1737476934,"startTime":"0","endTime":"0","summary":"北京时间2025年01月22日00时28分，Actinium Pharmaceuticals, Inc. 股票出现异动，股价快速跳水5.00%。Actinium Pharmaceuticals, Inc. 股票所在的生物技术行业中，整体涨幅为1.69%。其相关个股中，Channel Therapeutics Corporation、Dogwood Therapeutics, Inc.、Allakos Inc.涨幅较大，Dogwood Therapeutics, Inc.、Channel Therapeutics Corporation、Dermata Therapeutics, Inc.较为活跃，换手率分别为759.91%、478.61%、182.49%，振幅较大的相关个股有Channel Therapeutics Corporation、Klotho Neurosciences Inc C/Wts 21/06/2029 、Dogwood Therapeutics, Inc.，振幅分别为96.32%、41.33%、38.48%。Actinium Pharmaceuticals, Inc. 公司简介：Actinium Pharmaceuticals Inc是一家生物制药公司，致力于为缺乏有效治疗选择的癌症患者开发创新性靶向疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122002854986e488f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122002854986e488f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ATNM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2504152941","title":"Actinium Pharmaceuticals, Inc. (Delaware)盘中异动 快速拉升5.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2504152941","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2504152941?lang=zh_cn&edition=full","pubTime":"2025-01-18 03:37","pubTimestamp":1737142664,"startTime":"0","endTime":"0","summary":"北京时间2025年01月18日03时37分，Actinium Pharmaceuticals, Inc. 股票出现异动，股价大幅拉升5.51%。Actinium Pharmaceuticals, Inc. 股票所在的生物技术行业中，整体涨幅为0.47%。其相关个股中，Channel Therapeutics Corporation、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 、Revolution Medicines Inc C/Wts 17/12/2026 涨幅较大，Aditxt, Inc.、Channel Therapeutics Corporation、Phio Pharmaceuticals Corp.较为活跃，换手率分别为238.73%、55.32%、44.46%，振幅较大的相关个股有Channel Therapeutics Corporation、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 、Immatics N V C/Wts 01/07/2025 ，振幅分别为116.67%、53.37%、51.37%。Actinium Pharmaceuticals, Inc. 公司简介：Actinium Pharmaceuticals Inc是一家生物制药公司，致力于为缺乏有效治疗选择的癌症患者开发创新性靶向疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250118033744a225fdf5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250118033744a225fdf5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ATNM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503068559","title":"Actinium Pharmaceuticals, Inc. (Delaware)盘中异动 股价大跌5.49%报1.19美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503068559","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503068559?lang=zh_cn&edition=full","pubTime":"2025-01-15 03:52","pubTimestamp":1736884351,"startTime":"0","endTime":"0","summary":"北京时间2025年01月15日03时52分，Actinium Pharmaceuticals, Inc. 股票出现异动，股价大幅跳水5.49%。Actinium Pharmaceuticals, Inc. 股票所在的生物技术行业中，整体跌幅为0.81%。其相关个股中，Eterna Therapeutics Inc.、Jasper Therapeutics Inc C/Wts 24/09/2026 、Matinas Biopharma Holdings, Inc.涨幅较大，Eterna Therapeutics Inc.、Phio Pharmaceuticals Corp.、Soligenix, Inc.较为活跃，换手率分别为1078.81%、598.20%、420.96%，振幅较大的相关个股有Eterna Therapeutics Inc.、Matinas Biopharma Holdings, Inc.、Neurosense Therapeutics Ltd C/Wts 10/11/2026 ，振幅分别为170.74%、69.81%、69.33%。Actinium Pharmaceuticals, Inc. 公司简介：Actinium Pharmaceuticals Inc是一家生物制药公司，致力于为缺乏有效治疗选择的癌症患者开发创新性靶向疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115035231986636d1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115035231986636d1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ATNM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2502705159","title":"Actinium Pharmaceuticals, Inc. (Delaware)盘中异动 急速跳水5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2502705159","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2502705159?lang=zh_cn&edition=full","pubTime":"2025-01-09 01:38","pubTimestamp":1736357929,"startTime":"0","endTime":"0","summary":"北京时间2025年01月09日01时38分，Actinium Pharmaceuticals, Inc. 股票出现异动，股价快速下挫5.04%。Actinium Pharmaceuticals, Inc. 股票所在的生物技术行业中，整体涨幅为0.10%。其相关个股中，Sana Biotechnology, Inc.、Silo Pharma, Inc.、Vir Biotechnology, Inc.涨幅较大，Silo Pharma, Inc.、Nls Pharmaceutics Ltd.、60 Degrees Pharmaceuticals, Inc.较为活跃，换手率分别为3446.41%、599.31%、588.63%，振幅较大的相关个股有Sana Biotechnology, Inc.、Silo Pharma, Inc.、Conduit Pharmaceuticals Inc C/Wts 22/09/2028，振幅分别为192.73%、143.11%、89.00%。Actinium Pharmaceuticals, Inc. 公司简介：Actinium Pharmaceuticals Inc是一家生物制药公司，致力于为缺乏有效治疗选择的癌症患者开发创新性靶向疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250109013849a21a7c90&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250109013849a21a7c90&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ATNM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2500297539","title":"Actinium Pharmaceuticals, Inc. (Delaware)盘中异动 急速上涨5.16%报1.33美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2500297539","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2500297539?lang=zh_cn&edition=full","pubTime":"2025-01-02 23:49","pubTimestamp":1735832942,"startTime":"0","endTime":"0","summary":"北京时间2025年01月02日23时49分，Actinium Pharmaceuticals, Inc. 股票出现波动，股价大幅上涨5.16%。Actinium Pharmaceuticals, Inc. 股票所在的生物技术行业中，整体涨幅为0.79%。Actinium Pharmaceuticals, Inc. 公司简介：Actinium Pharmaceuticals Inc是一家生物制药公司，致力于为缺乏有效治疗选择的癌症患者开发创新性靶向疗法。，目前在急性髓样白血病的临床试验中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250102234902a2131511&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250102234902a2131511&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ATNM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2495611336","title":"Actinium Pharmaceuticals, Inc. (Delaware)盘中异动 股价大涨5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2495611336","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2495611336?lang=zh_cn&edition=full","pubTime":"2024-12-31 23:23","pubTimestamp":1735658606,"startTime":"0","endTime":"0","summary":"北京时间2024年12月31日23时23分，Actinium Pharmaceuticals, Inc. 股票出现异动，股价急速拉升5.13%。Actinium Pharmaceuticals, Inc. 股票所在的生物技术行业中，整体涨幅为0.53%。Actinium Pharmaceuticals, Inc. 公司简介：Actinium Pharmaceuticals Inc是一家生物制药公司，致力于为缺乏有效治疗选择的癌症患者开发创新性靶向疗法。，目前在急性髓样白血病的临床试验中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024123123232698569c4c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024123123232698569c4c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ATNM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.actiniumpharma.com","stockEarnings":[{"period":"1week","weight":-0.0167},{"period":"1month","weight":0.1683},{"period":"3month","weight":0.2041},{"period":"6month","weight":0.1919},{"period":"1year","weight":-0.2671},{"period":"ytd","weight":-0.1324}],"compareEarnings":[{"period":"1week","weight":-0.0102},{"period":"1month","weight":-0.0049},{"period":"3month","weight":0.0252},{"period":"6month","weight":0.1684},{"period":"1year","weight":0.1568},{"period":"ytd","weight":0.1227}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Actinium Pharmaceuticals, Inc.于1997年10月6日在内华达州注册成立。该公司曾是一家空壳公司，在市场上与合适的经营公司合并。该公司现在是一家生物制药公司，专注于抗癌药物的540亿美元的市场。该公司最先进的产品是Actimab -A ，含有AC-225抗体药物结构，目前在急性髓系白血病（AML）和Iomab-B——一种包含iodine131的抗体药物结构进行人体临床试验，用于造血干细胞移植时使用。该公司目前正在设计并申请一项造血干细胞移植的试验，主要针对老年患者难治的复发性急性髓系白血病。该公司正在利用其在放射免疫治疗领域的专业知识开发治疗癌症的药物。此外， AC-225为基础的药物开发依赖于专利的α粒子免疫治疗技术（ APIT ）平台，这是与Memorial Sloan Kettering癌症中心合作开发的技术，该中心的间接附属公司Actinium Holdings有限责任公司是制药公司的大股东。APIT技术与单克隆抗体结合时非常有效，但相对安全的α粒子会发射放射性同位素，尤其是锕225和铋213 ，最终药物结构的设计是专门针对并且杀死癌细胞，同时尽量减少副作用。该公司拟开发不同类型的癌症治疗产品，从与大型制药公司的合作和直接在专业市场销售其产品获得收益。","yearOnYearQuotes":[{"month":1,"riseRate":0.583333,"avgChangeRate":0.022838},{"month":2,"riseRate":0.416667,"avgChangeRate":-0.007484},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.052607},{"month":4,"riseRate":0.307692,"avgChangeRate":-0.033547},{"month":5,"riseRate":0.769231,"avgChangeRate":0.082746},{"month":6,"riseRate":0.153846,"avgChangeRate":-0.0432},{"month":7,"riseRate":0.384615,"avgChangeRate":-0.025354},{"month":8,"riseRate":0.307692,"avgChangeRate":-0.072035},{"month":9,"riseRate":0.461538,"avgChangeRate":0.033076},{"month":10,"riseRate":0.5,"avgChangeRate":0.047832},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.051055},{"month":12,"riseRate":0.25,"avgChangeRate":-0.057556}],"exchange":"AMEX","name":"Actinium Pharmaceuticals, Inc.","nameEN":"Actinium Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Actinium Pharmaceuticals, Inc.(ATNM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Actinium Pharmaceuticals, Inc.(ATNM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Actinium Pharmaceuticals, Inc.,ATNM,Actinium Pharmaceuticals, Inc.股票,Actinium Pharmaceuticals, Inc.股票老虎,Actinium Pharmaceuticals, Inc.股票老虎国际,Actinium Pharmaceuticals, Inc.行情,Actinium Pharmaceuticals, Inc.股票行情,Actinium Pharmaceuticals, Inc.股价,Actinium Pharmaceuticals, Inc.股市,Actinium Pharmaceuticals, Inc.股票价格,Actinium Pharmaceuticals, Inc.股票交易,Actinium Pharmaceuticals, Inc.股票购买,Actinium Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Actinium Pharmaceuticals, Inc.(ATNM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Actinium Pharmaceuticals, Inc.(ATNM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}